Episode 64. Lymphoma Updates from EHA and ICM...

In this episode, we dive deep into ASH 2025 updates on myeloid malignancies with Dr. Curtis Lachowiez. From the plenary halls of ASH 2025 to long-term follow-up of Aza/Ven/Gilteritinib, we unpack what the latest evidence means for the future of AML management.1. PARADIGM Trial (P ...  Show more

BloodCancerTalks: ASH 2025 Lymphoma RoundupGuest: Dr. Carla Casulo, Associate Professor, Wilmot Cancer Centre, University of RochesterAbstracts DiscussedFollicular LymphomaEPCORE-FL1 (Falchi) - Epcoritamab plus lenalidomide-rituximab (R2) in relapsed/refractory FLTheme: Bispecifi ...  Show more

Joseph Mikhael, MD, and Ashley Rosko, MD, discuss the role of comorbidities in multiple myeloma and stress the importance of shifting away from the sole use of age-based treatment decisions. Relevant disclosures can be found with the episode show notes on Medscape.com ( https://ww ...  Show more

Send us Fan MailNinja Nerds,Welcome to the Ninja Nerd Podcast with Zach and Rob! In this episode, we dive deep into Lymphoma, breaking down its pathogenesis, clinical presentation, and the latest advancements in treatment. We explore the key differences between Hodgkin and Non-Ho ...  Show more

In this week's episode, Blood editor Dr. Laura Michaelis interviews author Dr. Taylor Brooks on his latest paper published in volume 146 issue 18 of Blood Journal. The conversation discusses outcomes of bispecific antibodies (epcoritamab or glofitamab) in treating aggressive B-ce ...  Show more

Send us Fan MailNinja Nerds!In this episode of the Ninja Nerd Podcast, Zach and Rob discuss Colorectal Cancer. This comprehensive discussion focuses on the clinical presentation, pathogenesis, and management of one of the most common malignancies encountered in clinical practice. ...  Show more